Literature DB >> 20224977

Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol.

Manouchehr Nakhjavani1, Omid Khalilzadeh, Leila Khajeali, Alireza Esteghamati, Afsaneh Morteza, Arsia Jamali, Sheida Dadkhahipour.   

Abstract

Oxidized low-density lipoprotein (ox-LDL) plays a key role in the progression of atherosclerosis and diabetes complications. The aim of this study was first, to evaluate the association between ox-LDL and diabetes duration, and second, to examine serum level of ox-LDL in patients with prolonged diabetes and a desirable LDL-cholesterol level. A total of 36 type-2 diabetic patients with a diabetes duration of more than 5 years, 36 newly diagnosed diabetic patients, and 36 age-, sex- and BMI-matched healthy participants were recruited. Healthy participants and newly diagnosed patients were not receiving any treatment. All patients with prolonged diabetes had desirable LDL-cholesterol levels (<100 mg/dL), according to the adult treatment panel-III guidelines. While LDL-cholesterol was significantly lower in patients with diabetes duration >5 years, in comparison to newly diagnosed patients (P < 0.01), ox-LDL was significantly higher in patients with prolonged diabetes (P < 0.001). The ox-LDL-to-LDL ratio was dramatically higher in patients with diabetes duration >5 years in comparison to newly diagnosed patients and healthy participants (P < 0.001). Ox-LDL was significantly associated with diabetes duration (r = 0.519, P = 0.001). In multivariate analysis, this association remained significant (beta = 0.501, P = 0.003) after adjustment for potential confounders. In conclusion, this study showed that the serum ox-LDL level increases with the length of diabetes, even though the patients' LDL-cholesterol level is maintained at a desirable level. Our findings highlight that possibly more attention should be focused on markers of oxidative stress in the management of lipids in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224977     DOI: 10.1007/s11745-010-3401-8

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  44 in total

1.  Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population.

Authors:  Christa Meisinger; Jens Baumert; Natalie Khuseyinova; Hannelore Loewel; Wolfgang Koenig
Journal:  Circulation       Date:  2005-07-25       Impact factor: 29.690

2.  Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women.

Authors:  Annie Lapointe; Charles Couillard; Marie-Eve Piché; S John Weisnagel; Jean Bergeron; André Nadeau; Simone Lemieux
Journal:  Atherosclerosis       Date:  2006-05-04       Impact factor: 5.162

3.  Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation.

Authors:  N M Fisher; K Meksawan; A Limprasertkul; P J Isackson; D R Pendergast; G D Vladutiu
Journal:  J Inherit Metab Dis       Date:  2007-04-05       Impact factor: 4.982

Review 4.  Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

Authors:  P G Scheffer; T Teerlink; R J Heine
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

5.  Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes.

Authors:  R J Woodman; G F Watts; D A Playford; J D Best; D C Chan
Journal:  Diabetes Obes Metab       Date:  2005-09       Impact factor: 6.577

Review 6.  Hyperglycemia, lipoprotein glycation, and vascular disease.

Authors:  Arvindan Veiraiah
Journal:  Angiology       Date:  2005 Jul-Aug       Impact factor: 3.619

Review 7.  Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Authors:  P Holvoet
Journal:  Verh K Acad Geneeskd Belg       Date:  2008

8.  Effects of advanced glycation endproducts on the generation of macrophage-mediated oxidized low-density lipoprotein.

Authors:  J Matsui; T Onuma; N Tamasawa; T Suda
Journal:  J Diabetes Complications       Date:  1997 Nov-Dec       Impact factor: 2.852

9.  Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study.

Authors:  Manouchehr Nakhjavani; Alireza Esteghamati; Firouzeh Asgarani; Omid Khalilzadeh; Abdolrahim Nikzamir; Reza Safari
Journal:  Transl Res       Date:  2008-12-09       Impact factor: 7.012

10.  The protective effect of fluvastatin on hydroxyl radical generation by inhibiting low-density lipoprotein (LDL) oxidation in the rat myocardium.

Authors:  Toshio Obata; Hidetoshi Yonemoti; Masahiro Aomine
Journal:  Microvasc Res       Date:  2008-09-18       Impact factor: 3.514

View more
  28 in total

1.  Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients.

Authors:  Alliny de Souza Bastos; Dana T Graves; Ana Paula de Melo Loureiro; Carlos Rossa Júnior; Sâmia Cruz Tfaile Corbi; Fausto Frizzera; Raquel Mantuaneli Scarel-Caminaga; Niels Olsen Câmara; Oelisoa M Andriankaja; Meire I Hiyane; Silvana Regina Perez Orrico
Journal:  J Diabetes Complications       Date:  2016-07-21       Impact factor: 2.852

2.  Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study.

Authors:  Giovanni Zuliani; Mario Luca Morieri; Stefano Volpato; Giovanni B Vigna; Cristina Bosi; Marcello Maggio; Antonio Cherubini; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2012-10-11       Impact factor: 5.162

3.  Vitamin E conditionally inhibits atherosclerosis in ApoE knockout mice by anti-oxidation and regulation of vasculature gene expressions.

Authors:  Futian Tang; Meili Lu; Suping Zhang; Meng Mei; Tieqiao Wang; Peiqing Liu; Hongxin Wang
Journal:  Lipids       Date:  2014-11-11       Impact factor: 1.880

4.  Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages.

Authors:  Xiao Qun Wang; Ke Yang; Yu Song He; Lin Lu; Wei Feng Shen
Journal:  Lipids       Date:  2011-02-20       Impact factor: 1.880

5.  The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes.

Authors:  Mehryar Zargari; Fahimeh Sharafeddin; Abdolkarim Mahrooz; Ahad Alizadeh; Parisa Masoumi
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

6.  Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study.

Authors:  Liang He; Irina Culminskaya; Yury Loika; Konstantin G Arbeev; Olivia Bagley; Matt Duan; Anatoliy I Yashin; Alexander M Kulminski
Journal:  Exp Gerontol       Date:  2017-09-28       Impact factor: 4.032

Review 7.  Epigenetic regulation of inflammatory factors in adipose tissue.

Authors:  Byung Chul Jung; Sona Kang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-07-29       Impact factor: 4.698

8.  Beneficial effects of MgSO4 on TFAM, UPC3 and FNDC5 mRNA expressions in skeletal muscle of type 2 diabetic rats: a possible mechanism to improve insulin resistance.

Authors:  Farzaneh Yazdanimoghaddam; Mahmoud Aghaei; Maedeh Ghasemi; Nepton Soltani; Hossein Rezazadeh; Fouzieh Zadhoush
Journal:  Mol Biol Rep       Date:  2022-01-22       Impact factor: 2.316

9.  Estrogen Sulfotransferase is Highly Expressed in Vascular Endothelial Cells Overlying Atherosclerotic Plaques.

Authors:  Akira Sato; Hinako Watanabe; Miyuki Yamazaki; Eiko Sakurai; Keiichi Ebina
Journal:  Protein J       Date:  2022-01-20       Impact factor: 2.371

10.  Increased LDL susceptibility to oxidation accelerates future carotid artery atherosclerosis.

Authors:  Toshinari Aoki; Tsueko Abe; Eiji Yamada; Takayuki Matsuto; Masahiko Okada
Journal:  Lipids Health Dis       Date:  2012-01-09       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.